Kabasakal et al. [20] studied the absorbed dose of Lu-PSMA in different organs of seven patients with progressive PC who received a diagnostic dose of 177Lu-PSMA-617 with a mean activity of 192.6 ± 11.0 MBq. This evidence concerns the gene FOLH1 and pachyonychia congenita.